Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

ABSTRACT:

Background

The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice.

Methods

Cohorts were created using electronic healthcare databases from the UK, the Netherlands, Germany and Sweden. Patients with a first prescription of rivaroxaban or vitamin K antagonist during the period from December 2011 (in the UK, January 2012) to December 2017 (in Germany, December 2016) for venous thromboembolism indication, with no record of atrial fibrillation or recent cancer history, were observed until the occurrence of each safety outcome (hospitalization for intracranial, gastrointestinal, urogenital or ot

SUBMITTER: Ruigomez A 

PROVIDER: S-EPMC10919665 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature